Dyax Corporation

Astrazeneca Ab

Simon E Hufton

Hendricus Renerus Jacobus Mattheus Hoogenboom

Hendricus R J M Hoogenboom

Rene Hoet

Henk Pieters

Clive R Wood

Daniel T Dransfield

Maria Henderikx

Tom Goldschmidt

René Hoet

Henricus Hoogenboom

Christin V Andersson

Johanna Lindquist

Dan Sunnemark

Christer Nordstedt

Sergy Leonov

A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set). The use of such matched vector sets provides flexibility and versatility in the generation of eukaryotic display libraries, for example the ability to generate and to display multi-chain polypeptides by combining and recombining vectors that express variegations of the individual chains of a multi-chain polypeptide. Entire repertoires of novel chain combinations can be devised using such vector sets.

Multi-chain eukaryotic display vectors and uses thereof

A human antibody fragment, which antibody or fragment:

Methods of using an antibody that binds to apolipoprotein e

Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity.

Antibodies to Tie1 ectodomain

A human antibody fragment, which antibody or fragment: (i) binds to a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 of the C-terminal domain of Apolipoprotein E (ApoE-CTD) or the amino acid sequence of a part thereof; and (ii) binds to human plaques.

antibodies binding to a C-terminal fragment of apoliopoprotein E

Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity and angiogenesis. The agents can be used to treat angiogenesis-associated disorders.

Method of inhibition of vascular development using an antibody

Tie1 is a receptor tyrosine kinase protein that includes a transmembrane domain. Tie1 is present on endothelial cells. This disclosure described antibodies that bind to Tie1, including ones that inhibit endothelial cell activity.

Tie1-binding ligands

Growing community of inventors

Clitheroe Lanes, United Kingdom

Simon E Hufton